Monopar Therapeutics Inc

NASDAQ:MNPR  
2.64
0.00 (0.00%)
7:47:07 PM EDT: $2.57 -0.07 (-2.65%)
Earnings Announcements

Monopar Therapeutics Reports Third Quarter Results

Published: 11/10/2022 13:30 GMT
Monopar Therapeutics Inc (MNPR) - Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments.
Monopar Therapeutics Inc - Validive(®) Phase 2b/3 Interim Analysis on Track for Q1 2023.
Monopar Therapeutics Inc - Net Loss for Q3 of 2022 Was $2.4 Million Or $0.19 per Share.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.23

More details on our Analysts Page.